IP Verse

Taiho Pharmaceutical competitive analysis

Latest publications and patents of Taiho Pharmaceutical New

Explore the latest publications and patents granted to Taiho Pharmaceutical, showcasing their recent innovations and technological advancements.

Last updated on: Sep 28, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Taiho Pharmaceutical

EP3845537
Jul 30, 2025Crystal Of Pyrazolo[3,4-D]PyrimidineGranted And Under Opposition
EP1849470
Mar 20, 2024Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase InhibitorPatent Maintained As Amended
EP3042669
Mar 8, 2023Antitumor Agent And Antitumor Effect EnhancerGranted And Under Opposition
EP3012255
Oct 13, 2021Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For SameGranted And Under Opposition
EP2815752
May 20, 2020Oral Pharmaceutical CompositionGranted And Under Opposition
EP2815753
May 16, 2018Oral Pharmaceutical CompositionGranted And Under Opposition
EP2947086
Jan 3, 2018Novel Fused Pyrimidine Compound Or Salt ThereofNo Opposition Filed Within Time Limit

Latest patents of Taiho Pharmaceutical opposed by its competitors

Explore Taiho Pharmaceutical's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP1849470
Mar 20, 2024Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase Inhibitor2
EP3042669
Mar 8, 2023Antitumor Agent And Antitumor Effect Enhancer2
EP3012255
Oct 13, 2021Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For Same1
EP2815752
May 20, 2020Oral Pharmaceutical Composition1
EP2815753
May 16, 2018Oral Pharmaceutical Composition1

Latest PTAB cases involving Taiho Pharmaceutical

Discover the latest PTAB cases involving Taiho Pharmaceutical, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Taiho Pharmaceutical with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
TAIHO PHARMACEUTICAL - 7 - - Non-Active
GENERICS UK212 - - - Highly Aggressive
STADA ARZNEIMITTEL10828 - - Highly Aggressive
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive